Venture Capital News: Elucid Scores $55M Series D Round
2026-09-03
Tweet
BOSTON, MA, Elucid has announced the raise of $55 million in an oversubscribed Series D financing.
Elucid, a medical technology company using AI-powered, clinically validated software to advance precision diagnosis and treatment of cardiovascular disease, today announced the raise of $55 million in an oversubscribed Series D financing. The round brings Elucid's total funding raised to date to approximately $185 million and includes new participation from a large medtech company, which joins as Elucid's fourth publicly-traded strategic investor. The addition of this strategic investor to Elucid's syndicate of publicly traded partners underscores the growing industry confidence in Elucid's approach to non-invasive cardiovascular diagnostics.
The Series D also includes participation from other new and existing investors, including IAG Capital Partners and Elevage Medical Technologies, a platform created by Patient Square Capital. Proceeds from the financing will be used to accelerate commercial expansion of Elucid's comprehensive clinical platform, including FFR-CT (510(k) submission currently under FDA review) and Plaque-IQ™, as well as to continue Elucid's leadership in novel AI R&D and in advancing the field through landmark clinical studies.
Elucid is a medical technology company that develops AI to see invisible features of cardiovascular risk. The company is dedicated to developing a clinical platform to help physicians deliver CCTA-guided personalized care by providing a more precise view of atherosclerosis, the root cause of cardiovascular disease. The company's FDA-cleared Plaque-IQ™ image analysis software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk of disease. Plaque-IQ equips physicians with critical information regarding the type and amount of plaque in arteries that can lead to heart attack and stroke. Elucid is also pursuing an indication for FFR-CT, which helps physicians identify coronary blockages and the extent of a patient's ischemia non-invasively. Elucid's BioIntegrated FFR-CT product, which integrates anatomy, plaque biology, and physiology, is derived from its plaque algorithm, resulting in concordance with its plaque analysis.
The Series D also includes participation from other new and existing investors, including IAG Capital Partners and Elevage Medical Technologies, a platform created by Patient Square Capital. Proceeds from the financing will be used to accelerate commercial expansion of Elucid's comprehensive clinical platform, including FFR-CT (510(k) submission currently under FDA review) and Plaque-IQ™, as well as to continue Elucid's leadership in novel AI R&D and in advancing the field through landmark clinical studies.
Elucid is a medical technology company that develops AI to see invisible features of cardiovascular risk. The company is dedicated to developing a clinical platform to help physicians deliver CCTA-guided personalized care by providing a more precise view of atherosclerosis, the root cause of cardiovascular disease. The company's FDA-cleared Plaque-IQ™ image analysis software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk of disease. Plaque-IQ equips physicians with critical information regarding the type and amount of plaque in arteries that can lead to heart attack and stroke. Elucid is also pursuing an indication for FFR-CT, which helps physicians identify coronary blockages and the extent of a patient's ischemia non-invasively. Elucid's BioIntegrated FFR-CT product, which integrates anatomy, plaque biology, and physiology, is derived from its plaque algorithm, resulting in concordance with its plaque analysis.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors
